On March 3, 2014 Roche announced that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy (Press release Hoffmann-La Roche, MAR 3, 2014, View Source [SID:1234500215]).
The study evaluated if onartuzumab (MetMab) in combination with Tarceva (erlotinib) helped patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose tumors were identified as MET-positive live longer compared to Tarceva alone. Overall adverse event rates were generally similar between the two groups. Data will be submitted for presentation at a forthcoming medical meeting.
Roche is evaluating the implications of the METLung study results across the ongoing onartuzumab clinical programme.